A detailed history of Versant Capital Management, Inc transactions in Intellia Therapeutics, Inc. stock. As of the latest transaction made, Versant Capital Management, Inc holds 150 shares of NTLA stock, worth $1,530. This represents 0.0% of its overall portfolio holdings.

Number of Shares
150
Holding current value
$1,530
% of portfolio
0.0%

Shares

5 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2024

Jan 02, 2025

BUY
$11.41 - $21.09 $1,711 - $3,163
150 New
150 $1,000
Q2 2024

Jul 05, 2024

BUY
$20.02 - $27.22 $1,361 - $1,850
68 Added 400.0%
85 $1,000
Q1 2024

Apr 03, 2024

SELL
$23.82 - $32.8 $238 - $328
-10 Reduced 37.04%
17 $0
Q4 2023

Jan 08, 2024

BUY
$23.16 - $32.34 $625 - $873
27 New
27 $0
Q2 2023

Jul 10, 2023

BUY
$34.58 - $46.03 $691 - $920
20 New
20 $0

Others Institutions Holding NTLA

About Intellia Therapeutics, Inc.


  • Ticker NTLA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 76,011,800
  • Market Cap $775M
  • Description
  • Intellia Therapeutics, Inc., a genome editing company, focuses on the development of therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; and NTLA-2002 for the treatment of hereditary angioedema, as well as other liver-focused programs comprising hemoph...
More about NTLA
Track This Portfolio

Track Versant Capital Management, Inc Portfolio

Follow Versant Capital Management, Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Versant Capital Management, Inc, based on Form 13F filings with the SEC.

News

Stay updated on Versant Capital Management, Inc with notifications on news.